To cope with the global bacterial multidrug resistance, scientific communities have devoted significant efforts to develop novel antibiotics, particularly those with new modes of actions. Teixobactin, recently isolated from uncultured bacteria, is considered as a promising first-in-class drug candidate for clinical development. Herein, we report its total synthesis by a highly convergent Ser ligation approach and this strategy allows us to prepare several analogues of the natural product.Department of Applied Biology and Chemical Technolog
Teixobactin, targeting lipid II, represents a new class of antibiotics with novel structures and has...
The cyclic depsipeptide, teixobactin, kills a number of Gram-positive bacteria, including methicilli...
The cyclic depsipeptide, teixobactin, kills a number of Grampositive bacteria, including methicillin...
To cope with the global bacterial multidrug resistance, scientific communities have devoted signific...
The discovery of the new antibiotic teixobactin has been timely in the race for unearthing novel ant...
The discovery of antibiotics has led to the effective treatment of bacterial infections that were ot...
The development of bacterial resistance over time combined with the lack of novel compounds has resu...
The discovery of antibiotics has led to the effective treatment of bacterial infections that were ot...
Multi-drug resistant bacteria that are primarily unresponsive towards the available marketed antibio...
The first total synthesis of the cyclic depsipeptide natural product teixobactin is described. Synth...
The first synthesis and biological activity of a teixobactin analogue is reported. Substitution of t...
The recently discovered cyclic depsipeptide, teixobactin, is a highly potent antibiotic against mult...
Increasing bacterial resistance against current antibiotics and lack of new molecules to combat bact...
Following the widespread use and abuse of antibiotics, bacteria have evolved a diverse array of stra...
Teixobactin, a recently discovered depsipeptide that binds to bacterial lipid II and lipid III, prov...
Teixobactin, targeting lipid II, represents a new class of antibiotics with novel structures and has...
The cyclic depsipeptide, teixobactin, kills a number of Gram-positive bacteria, including methicilli...
The cyclic depsipeptide, teixobactin, kills a number of Grampositive bacteria, including methicillin...
To cope with the global bacterial multidrug resistance, scientific communities have devoted signific...
The discovery of the new antibiotic teixobactin has been timely in the race for unearthing novel ant...
The discovery of antibiotics has led to the effective treatment of bacterial infections that were ot...
The development of bacterial resistance over time combined with the lack of novel compounds has resu...
The discovery of antibiotics has led to the effective treatment of bacterial infections that were ot...
Multi-drug resistant bacteria that are primarily unresponsive towards the available marketed antibio...
The first total synthesis of the cyclic depsipeptide natural product teixobactin is described. Synth...
The first synthesis and biological activity of a teixobactin analogue is reported. Substitution of t...
The recently discovered cyclic depsipeptide, teixobactin, is a highly potent antibiotic against mult...
Increasing bacterial resistance against current antibiotics and lack of new molecules to combat bact...
Following the widespread use and abuse of antibiotics, bacteria have evolved a diverse array of stra...
Teixobactin, a recently discovered depsipeptide that binds to bacterial lipid II and lipid III, prov...
Teixobactin, targeting lipid II, represents a new class of antibiotics with novel structures and has...
The cyclic depsipeptide, teixobactin, kills a number of Gram-positive bacteria, including methicilli...
The cyclic depsipeptide, teixobactin, kills a number of Grampositive bacteria, including methicillin...